Samantha has led discovery, diagnostic and clinical development project teams out to Phase 3, seeing more than 20 candidate drugs through preclinical testing, and many into clinical testing. Passionate about using biomarkers to make decisions in early clinical development, in 2010 Samantha built and headed the first Translational Science function at AstraZeneca with the mandate to identify, develop and deliver suitable and timely segmentation, pharmacodynamic and efficacy biomarkers for CNS & pain projects to better inform and clarify decision making during early development and with the aim to improve probability of success in Phase 2 clinical studies. Samantha has a BSc and PhD in Biochemistry from the University of Dundee in Scotland, and conducted research at the Neurosurgery Department, Brigham & Women’s Hospital, Harvard Medical School in Boston, and The Center for Neuroscience Research at The Burnham Institute in San Diego.
Keith is a clinician scientist, leading research that investigates the biology of cardiovascular disease and inflammation, particularly using genetic models, linking these with clinical and translational research in patients. A particular focus is the importance of redox signaling and therapeutic targets in the nitric oxide pathway.
Richard has published extensively in peer-reviewed scientific journals on neuroscience drug discovery, translational biomarkers and the use of biomedical imaging in drug discovery and development. He received the Gary Neil Award for “Innovation in Drug Development” by the American Society of Clinical Pharmacology and Therapeutics for his work on imaging in drug discovery and development and the first Sir James Black Award for Drug Discovery by the British Pharmacological Society.
David has previously led partner line support functions and licensing activities within Neusentis. Before that he led the Internal Medicine Research Unit and the Biomarkers Department for Pfizer at their R&D site in Sandwich, UK. He is an in vivo expert who has run teams in Sexual Health & Urology at Pfizer and Neuroscience at Lundbeck (Copenhagen, Denmark) and Merck Sharp & Dohme (Harlow, UK). David holds a BA in Natural Sciences and a PhD in Neuropharmacology, both from the University of Cambridge.